Next Investors logo grey

Halucenex agreement to give CPH another leg up in psychedelics


Published 31-MAR-2021 13:40 P.M.


5 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Creso Pharma’s (ASX: CPH) pending acquisition of Halucenex Life Sciences should prove to be an astute move, with Halucenex continuing to rapidly move towards its goal of developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets.

Halucenex is focused on progressing clinical trials to research the efficacy of psilocybin to treat and alleviate Treatment Resistant Depression in individuals suffering from PTSD and other mental illnesses.

Its clinical trials will explore the efficacy of psychedelic molecules on a range of mental health conditions such as depression and Post Traumatic Stress Disorder.

Finfeed recently reported that Halucenex was preparing for PTSD clinical trials.

Today, the company has entered into an agreement with medical and recreational extraction specialists, Advanced Extraction Systems Inc. (AESI) for the purchase of a custom-made CO2 Supercritical Extraction System for the purpose of producing consistent, high quality psychedelic extracts from psilocybin mushrooms.

AESI is based in Charlottetown, Canada and specialises in the design, engineering and fabrication of supercritical fluid CO2 extraction systems with a specific focus on the medical and recreational cannabis and hemp industries.

Halucenex will spend approximately 6-8 weeks designing and installing the CO2 Supercritical Extraction System at its onsite laboratory for an approximate cost of $70,000.

The extraction system is being built in preparation for the receipt of its Dealer’s License.

The Dealer’s License from Health Canada, will enable Halucenex to apply for a License Amendment to allow the production of botanical psychedelic extracts from psilocybin mushrooms for use future research and development of a range of different delivery methods including tinctures, lozenges, nasal sprays and capsules amongst others.

The licence amendment is expected to be received 45 days after receipt of the Dealer’s License.

“This agreement with AESI is a major development for a number of reasons, Halucenex Founder & CEO Bill Fleming said.

“Firstly, the ability to extract psychedelic compound concentrates will allow us to progress the development of a number of delivery methods with broad applicability, including capsules, sprays, tinctures and lozenges amongst others, which may result in a higher standard of treatment.

“Additionally, the extracted product will allow us to analyse, characterise and compare the major components in various psilocybe mushroom strains through our established laboratory setting, leading to initial research and the potential entourage effects of psychedelic compounds.

“Further, we anticipate that considerable future research will be undertaken between synthetic and botanical psilocybin to fully understand the benefits it can offer. Having the extraction system in place and the ability to produce solvent-free distillate in-house will be key for future comparative bioactivity studies.”

Extraction system is a major move forward

The agreement with AESI is a major development for Halucenex and provides a pivotal building block for future product development initiatives.

It also gives Halucenex increased security over the future supply of psilocybin. This means that Halucenex will be less reliant on third parties for in- demand psilocybin supply.

Further to this, it allows Halucenex to have better control over the timelines for research and product development.

Subject to the receipt of its Dealers License, and subsequent License Amendment, Halucenex will use the Supercritical Extraction System to breakdown the various psychedelic compounds of botanical psilocybin for future product development.

It will also explore the efficacy of extracted distillates or concentrates in various delivery mechanisms to explore faster compound onset, more effective dosing which can lead to a better patient experience and more positive treatment outcomes.

The accumulation of intellectual property and understanding of various psychedelic compounds in this under researched, but growing space is critical for de-risking the path to commercialisation.

Understanding the various psychedelic compounds which can be extracted from psychedelic psilocybin mushrooms also paves the way for patenting both the compound, and the way in which it is used to deliver desired patient outcomes.

Halucenex will not, at this stage, use the new extraction machine to produce its own naturally derived psilocybin in its upcoming clinical trials, as currently Health Canada prefers the use of synthetic active pharmaceutical ingredient (API) due to the fact that natural psilocybin has yet to be fully certified in a GMP environment.

However, through the use of the extraction system, Halucenex is looking to create a GMP certified extract, which it then intends to use in future clinical trials to provide a naturally extracted product for safe, evidence-based psilocybin-assisted psychotherapies and optimise psilocybe mushrooms in order to standardise extracts, thereby increasing efficacy.

It is very pleasing to see Halucenex make such significant progress in a short period of time, Non-executive Chairman Adam Blumenthal said.

“The agreement with AESI and subsequent fabrication of a leading extraction system will provide Creso and Halucenex with a first mover advantage in terms of psychedelic product and delivery methods, which could in turn lead to a number of revenue generating and treatment outcome opportunities.

“The Company has a number of growth initiatives planned in the near term across North America and Europe and we look forward to providing ongoing updates to shareholders.”

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.